DOM-ANAGRELIDE CAPSULE

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

ANAGRELIDE (ANAGRELIDE HYDROCHLORIDE MONOHYDRATE)

Sẵn có từ:

DOMINION PHARMACAL

Mã ATC:

L01XX35

INN (Tên quốc tế):

ANAGRELIDE

Liều dùng:

0.5MG

Dạng dược phẩm:

CAPSULE

Thành phần:

ANAGRELIDE (ANAGRELIDE HYDROCHLORIDE MONOHYDRATE) 0.5MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

100

Loại thuốc theo toa:

Prescription

Khu trị liệu:

PLATELET-REDUCING AGENTS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0131875001; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2006-06-16

Đặc tính sản phẩm

PRODUCT MONOGRAPH
PR
DOM-ANAGRELIDE
Anagrelide Capsules, House Standard
0.5 mg
PLATELET-REDUCING AGENT
DOMINION PHARMACAL
6111 Royalmount Avenue, Suite #100
Montréal, Québec
H4P 2T4 DATE OF REVISION:
May 18, 2017
SUBMISSION CONTROL NO.: 205385
_ _
_Dom-ANAGRELIDE Product Monograph _
_Page 2 of 32_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................................................
3
SUMMARY PRODUCT INFORMATION
.....................................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................................
3
CONTRAINDICATIONS
...............................................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................................
4
ADVERSE REACTIONS
................................................................................................................................
7
DRUG INTERACTIONS
..............................................................................................................................
10
DOSAGE AND ADMINISTRATION
..........................................................................................................
12
OVERDOSAGE
............................................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................................
13
STORAGE AND STABILITY
......................................................................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
..........................................................................
17
PART II: SCIENTIFIC INFORMATION
.................................